Illumina (ILU.DE) Stock Analysis & Winston Score

Illumina makes machines that read DNA. Scientists, hospitals, and drug companies use these machines to study genes — which helps them find diseases, develop new medicines, and understand how living things work. Illumina is the dominant player in a field called DNA sequencing, and its equipment is used in research labs across the world. The company sells sequencing machines upfront and then earns recurring revenue by selling the chemical kits and supplies needed to run each test — a classic "razor and blades" model. Illumina operates globally, with customers in North America, Europe, and Asia, and its high gross margins reflect how deeply its technology is embedded in research workflows, making it costly for labs to switch. The key growth driver is the expanding use of genomic testing in clinical medicine, particularly cancer screening, though the company faces risk from emerging competitors offering cheaper sequencing platforms that could erode its long-held market dominance.